Previously work has shown that a tandem CAR approach targeting HER2 and IL13Rα232 or trivalent CARs with Ephα233 in adult glioblastoma, can help mitigate tumor antigen escape which led to a dose escalation clinical trial.34 Given the results from this and previous studies HER2 targeting in a multi antigen approach should be further explored in the context of more diffuse gliomas such as pediatric DIPG. This evidence concerns the gene ERBB2 and neoplasm.